Opus Genetics Secures Major Non-Dilutive Funding Facility

Opus Genetics ( (IRD) ) just unveiled an update.

On April 2, 2026, Opus Genetics entered into a senior secured note purchase agreement providing access to up to $155 million in non-dilutive funding from Oberland Capital, with $105 million committed and an initial $35 million tranche expected to close on April 20, 2026. The seven-year notes, partially interest-only and secured by substantially all company assets, include a limited conversion feature into common stock at $6.72 per share and are structured around milestone-based tranches, including those tied to regulatory progress for lead gene therapy OPGx-LCA5.

Concurrently on April 2, 2026, the company agreed to a $5 million private placement of 1,116,070 common shares at $4.48 each, with anti-dilution protection for investors if future equity is issued below that price and a commitment by Opus to register the resale of these securities. Together with roughly $100 million of existing cash, the financing is expected to extend Opus’s runway into 2029, enabling acceleration of its inherited retinal disease pipeline—including pivotal studies and potential approvals for OPGx-LCA5 and OPGx-BEST1 and planned clinic entries for RDH12, MERTK, and RHO programs—while reinforcing its position in gene therapy and reducing near-term funding risk for shareholders.

The most recent analyst rating on (IRD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.

Spark’s Take on IRD Stock

According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.

The score is held back primarily by weak financial performance (declining revenue, large losses, and accelerating cash burn). This is partially offset by strong technical positioning (price above key moving averages with positive MACD) and supportive corporate developments, including recent financing and pipeline milestone progress. Valuation is a secondary drag given negative earnings and no dividend support.

To see Spark’s full report on IRD stock, click here.

More about Opus Genetics

Opus Genetics Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases. Its pipeline includes seven AAV-based programs led by OPGx-LCA5 and OPGx-BEST1, alongside additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK, as well as a small-molecule ophthalmic therapy.

The company targets severe retinal disorders with one-time, durable genetic treatments and is also advancing Phentolamine Ophthalmic Solution 0.75% beyond its approved use for pharmacologically induced mydriasis. Based in Research Triangle Park, N.C., Opus operates in a niche, high-unmet-need segment of ophthalmology, positioning itself as a specialist player in inherited retinal disease gene therapy.

Average Trading Volume: 941,757

Technical Sentiment Signal: Hold

Current Market Cap: $323.7M

For a thorough assessment of IRD stock, go to TipRanks’ Stock Analysis page.